Literature DB >> 3143537

Expression of HLA-DR antigens in inflammatory bowel disease mucosa: role of intestinal lamina propria mononuclear cell-derived interferon gamma.

O Y Qin1, M el-Youssef, B Yen-Lieberman, W Sapatnekar, K R Youngman, K Kusugami, C Fiocchi.   

Abstract

The expression of HLA-DR antigens on the surface of immune cells is crucial for appropriate antigen presentation and a normal immune response. In the intestinal mucosa involved by Crohn's disease and ulcerative colitis the expression of HLA-DR antigens is increased in both immune and nonimmune cells, a phenomenon probably mediated by soluble factors, such as interferon gamma, produced by locally activated mononuclear cells. This study investigated the production of interferon gamma by inflammatory bowel disease and control intestinal lamina propria mononuclear cells, and the ability of this endogenously produced lymphokine to induce expression of HLA-DR antigens on the monocytic cell lines U937 and ML3. After in vitro stimulation with interleukin 2 or phytohemagglutinin, but not spontaneously, lamina propria mononuclear cells produced variable amounts of interferon gamma, and their culture supernatants could induce de novo expression of HLA-DR antigens on the monocytic indicator cells. When the mononuclear cells were derived from inflammatory bowel disease mucosa, both the amount of interferon gamma present in the supernatants and the number of HLA-DR-positive cells induced by these supernatants were decreased as compared to controls. These results suggest that, in inflammatory bowel disease, interferon gamma may not be the only mediator of HLA-DR induction in the gut and that other soluble factors or agents, alone or interacting with interferon gamma, may also be responsible for this event, resulting in the enhanced HLA-DR antigen expression observed in the inflamed intestinal mucosa.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143537     DOI: 10.1007/bf01535942

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  43 in total

1.  Gut mucosal lymphocytes in inflammatory bowel disease: isolation and preliminary functional characterization.

Authors:  C Fiocchi; J R Battisto; R G Farmer
Journal:  Dig Dis Sci       Date:  1979-09       Impact factor: 3.199

2.  Immunoelectron microscopic localization of HLA-DR antigen in control small intestine and colon and in inflammatory bowel disease.

Authors:  I Hirata; L L Austin; W H Blackwell; J R Weber; W O Dobbins
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199

3.  Immune complex effects on murine macrophages. I. Immune complexes suppress interferon-gamma induction of Ia expression.

Authors:  H W Virgin; G F Wittenberg; E R Unanue
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

4.  Viral particles induce Ia antigen expression on astrocytes.

Authors:  P T Massa; R Dörries; V ter Meulen
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

5.  Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease.

Authors:  W S Selby; G Janossy; D Y Mason; D P Jewell
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

6.  Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines.

Authors:  V E Kelley; W Fiers; T B Strom
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

7.  Membrane differentiation in human myeloid cells: expression of unique profiles of cell surface glycoproteins in myeloid leukemic cell lines blocked at different stages of differentiation and maturation.

Authors:  M Fukuda; H P Koeffler; J Minowada
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

8.  Recombinant interferon-gamma increases HLA-DR synthesis and expression.

Authors:  T Y Basham; T C Merigan
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Supernatants of human leukocytes contain mediator, different from interferon gamma, which induces expression of MHC class II antigens.

Authors:  G Groenewegen; M de Ley; G M Jeunhomme; W A Buurman
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

10.  Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity.

Authors:  P S Steeg; R N Moore; H M Johnson; J J Oppenheim
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  16 in total

1.  Characterisation and quantification of mucosal cytokine that induces epithelial histocompatibility locus antigen-DR expression in inflammatory bowel disease.

Authors:  J R Lowes; P Radwan; J D Priddle; D P Jewell
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 2.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.

Authors:  T T MacDonald; P Hutchings; M Y Choy; S Murch; A Cooke
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

4.  Local and systemic liberation of proinflammatory cytokines in ulcerative colitis.

Authors:  M Gotteland; M Lopez; C Muñoz; R Saez; H Altshiller; P Llorens; O Brunser
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

5.  Class II (HLA-DR, -DP, and -DO) antigens on intestinal epithelia in ulcerative colitis, Crohn's disease, colorectal cancer and normal small intestine.

Authors:  Y Horie; M Chiba; M Iizuka; O Masamune
Journal:  Gastroenterol Jpn       Date:  1990-10

6.  Expression of MHC class II antigens (HLA-DR, -DP, and -DQ) on human gastric epithelium.

Authors:  N Ishii; M Chiba; M Iizuka; H Watanabe; T Ishioka; O Masamune
Journal:  Gastroenterol Jpn       Date:  1992-02

7.  Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease.

Authors:  F Autschbach; G Schürmann; L Qiao; H Merz; R Wallich; S C Meuer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa.

Authors:  E Breese; C P Braegger; C J Corrigan; J A Walker-Smith; T T MacDonald
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

9.  Expression of the 40 kD protein in DLD-1 colon cancer cells and the effect of cytokines.

Authors:  K M Das; L Squillante; F Robertson
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

10.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.